SCHEMBL30303908

SCHEMBL30303908

C=C(C)C(=O)Nc1ccc(-c2c(-c3ccc(Oc4nccc(Cl)n4)c(F)c3)c3c(N)ncnc3n2C)cc1

nearest known ligand 0.85

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 3/20 0.85
▸ FGFR4 P22455 3/20 0.85
▸ FGFR2 P21802 2/20 0.85
▸ FGFR3 P22607 2/20 0.85
▸ CYP3A4 P08684 1/20 0.85
▸ CYP2D6 P10635 1/20 0.85
▸ CYP2C9 P11712 1/20 0.85
▸ CYP2C19 P33261 1/20 0.85
▸ MAPT P10636 1/20 0.37
▸ BTK Q06187 1/20 0.36
▸ PIK3CD O00329 1/20 0.34
▸ MET P08581 8/20 0.34
▸ RET P07949 3/20 0.34
▸ AXL P30530 2/20 0.34
▸ KDR P35968 3/20 0.33
▸ KIT P10721 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22677027 1.00 FGFR1 (0.85) FGFR1FGFR4FGFR2FGFR3CYP3A4
Lirafugratinib SCHEMBL30303579 0.92 FGFR1 (1.00) FGFR1FGFR4FGFR2FGFR3CYP3A4
Lirafugratinib SCHEMBL22676186 0.92 FGFR1 (1.00) FGFR1FGFR4FGFR2FGFR3CYP3A4
Lirafugratinib SCHEMBL29728045 0.91 FGFR1 (0.99) FGFR1FGFR4FGFR2FGFR3CYP3A4
SCHEMBL30303562 0.91 FGFR1 (0.84) FGFR1FGFR4FGFR2FGFR3CYP3A4
SCHEMBL22677025 0.91 FGFR1 (0.84) FGFR1FGFR4FGFR2FGFR3CYP3A4
SCHEMBL22676266 0.90 FGFR1 (0.83) FGFR1FGFR4FGFR2FGFR3CYP3A4
SCHEMBL22675798 0.90 FGFR1 (0.83) FGFR1FGFR4FGFR2FGFR3CYP3A4
SCHEMBL30303435 0.90 FGFR1 (0.83) FGFR1FGFR4FGFR2FGFR3CYP3A4
SCHEMBL30303796 0.90 FGFR1 (0.83) FGFR1FGFR4FGFR2FGFR3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522605-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-11780845-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF D.E. SHAW RESEARCH, LLC 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR4 4/4885FGFR2 2/4885
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR4 4/4885FGFR2 2/4885
US-11780845-B2 FGFR inhibitors and methods of use thereof FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR4 4/4885FGFR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback